Cross-Platform Inspiration: Adapting Viral Vector “Self-Destruct” Switches to mRNA Therapeutics

Gene therapies and CAR-T cells often include inducible “suicide switches” to mitigate risks of persistent or off-target activity. Yet, mRNA therapeutics—while transient by nature—could also benefit from on-demand safety controls, especially for high-dose or repeated administration. Inspired by approaches in cell therapy and viral vectors (see Pereira, 2023), one could encode small-molecule-activated RNA-cleaving ribozymes or engineered “kill switches” within the mRNA payload itself, or as part of the delivery vehicle, allowing rapid deactivation in the event of adverse reactions or to limit duration of antigen expression. This would add a new layer of controllability and safety to mRNA drugs, addressing regulatory and ethical concerns as their use expands beyond vaccines to chronic diseases and personalized therapeutics. This conceptual transfer—applying safety engineering from other platforms to mRNA—remains largely unexplored in current mRNA literature.

References:

1. Nanotechnology-Driven Delivery Systems in Inoculation Therapies.. G. C. Pereira (2023). Methods in molecular biology.